Eris Lifesciences Revenue and Competitors

The journey of Eris Lifesciences began in 2007, focusing on the chronic drug segments of cardiology and diabetes. This Ahmedabad based emerging pharmaceutical major now ranks among the top 25 pharmaceutical companies in the Indian Pharmaceutical Market (IPM). In 2017, Eris made a public offer of its shares and is listed on the Bombay Stock Exchange (Code: 540596) and National Stock Exchange (Code: ERIS). Eris derives 66% of its revenues from the chronic segment, where it ranks among the top 20 players in the cardio and anti-diabetes therapeutic groups in the IPM. Recently, Eris forayed into the Central Nervous System (CNS) category, strengthening its presence in the top three chronic segments. The Company also has the biggest market share for the Vitamin D product. The genesis of Eris was rooted in the understanding of healthcare delivery gaps in an emerging country like India. Realizing the challenges of poor diagnosis, poor patient compliance, population-provider burden, etc. and the limitations of a single company to address these challenges, Eris adopted a partnering mindset and approach by aligning with like-minded institutions and adopting innovative programmes for engagement. Eris Lifesciences is a young company which imbibes qualities of youth - imagination, courage and passion.